The COVID-19 outbreak has created a global race for research into a vaccine, diagnostic and therapeutic among research institutes, governments, and big-tech pharmaceutical companies (Big Pharma). In this context, intellectual property rights (IPRs) play a prominent role in incentivizing COVID-19 vaccines. Simultaneously, IPRs, particularly the patent rights of Big Pharma, create restrictions on fair access to affordable COVID-19 vaccines. Besides, economically powerful high-income countries have purchased and reserved a large amount of COVID-19 vaccines while low and middle-income countries (LMICs) have been struggling to obtain sufficient vaccine doses. These factors have contributed to increasing the gap of access to affordable COVID-19 vaccines between high-income countries and LMICs. Having foreseen the likely effect of LMICs being discriminated against in the global COVID-19 vaccine production and distribution, the global community has already made some efforts to revisit the normative aspects of IPRs by making intellectual property a common good to achieve global health during the pandemic. For example, the World Health Organization (WHO) has launched the COVID-19 Technology Access Pool (C-TAP), considering the proposal made by Costa Rica. The C-TAP intended to ensure technology transfer, disclosure of research, flexible licensing and open innovations. However, Big Pharma and some high-income countries have criticised and directly interfered in the effective functioning of C-TAP. Therefore, there remains a question as to whether the C-TAP approach would only be idealistic or realistic in the global governance of IPRs and public health. Accordingly, this paper critically analyses the prospects that C-TAP would offer LMICs to overcome IPRs-related barriers and resource constraints in accessing the COVID-19 vaccine and reflect on how to tackle Big Pharma and some high-income countries’ influences on the effective functioning of C-TAP.
The COVID-19 outbreak has created a global race for research into a vaccine, diagnostic and therapeutic (COVID-19 treatments) among research institutes, governments, and big-tech pharmaceutical companies (Big Pharma). In this context, intellectual property rights (IPRs) would play a prominent role in incentivizing and accelerating COVID-19 treatments. However, there remains a reasonable doubt whether IPRs, in particular patent rights, would restrict access to COVID-19 treatments, and thereby create global health inequalities. Big Pharma may rely heavily on their IPRs to secure their patent monopoly and profit motives in successful development of COVID-19 treatments. Besides, Big Pharma has a history of using every possible tactic to circumvent the proposals to facilitate public health. This has led the global community to revisit the normative aspects of IPRs and consider making intellectual property a common good to achieve global health during the pandemic. As a result, the World Health Organization (WHO) has launched the COVID-19 Technology Access Pool (C-TAP), considering the proposal made by Costa Rica. The C-TAP intends to ensure technology transfer, disclosure of research, flexible licensing and open innovations. At the same time, Big Pharma, and proxy governments such as the United States of America, have already criticized this global initiative. Therefore, there remains a question as to whether a C-TAP approach would only be idealistic or realistic in the global governance of IPRs and public health. Accordingly, the main objective of this paper is to critically analyze the prospects that C-TAP would bring to combat COVID-19 pandemic with particular reference to the potential challenges that may be exerted by Big Pharma. This is legal doctrinal research performed through an extensive review of primary and secondary sources. Finally, this paper intends to reflect on how to tackle Big Pharma's influences on the effective functioning of C-TAP to ensure that everyone gets a fair opportunity to access and afford COVID-19 treatments. Keywords: IPRs, common good, COVID-19 treatments, C-TAP, Big Pharma
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.